Twenty-six New Zealand biotech companies and universities joined BIOTechNZ, New Zealand Trade and Enterprise and the Ministry of Business, Innovation and Employment as the New Zealand delegation to BIO 2019 in Philadelphia, 3-6 June.
The attending companies were:
- Argenta
- AFT Pharmaceuticals
- Avalia Immunotherapies
- Baldwins
- Blue Penguin
- Brandon Capital
- Cure Kids Ventures
- GlycoNZ
- Henry Hughes IP
- HoneyLab
- Kode Biotech
- Lipid and Diabetes Research
- Living Cell Technologies
- Massey University
- Medical Research Institute NZ
- Middlemore Clinical Trials
- New Zealand Association of Clinical Research (NZAcres)
- Optimal Clinical Trials Ltd
- Otago Innovation
- P3 Research Ltd
- Pacific Clinical Research Network
- Pharmacutical Solutions
- Pictor
- Spot Check Technologies
- Uniservices
- Viclink
The New Zealand delegation would not have happened without the hard work of:
- Friederike Steinebach – Programme Manager, MBIE
- Aliki Weststrate – Senior Stakeholder Engagement Advisor, MBIE
- Kimberlee Jordan – Senior Commercialisation Manager, Auckland UniServices
Additional thanks go to the following people for their support and hospitality:
- Kjesten Wiig (Innovative Partnerships, MBIE)
- James Araci (Callaghan Innovation)
- Mike Hearn (American Chamber of Commerce in New Zealand)
- Pip Ashford (Visit Anaheim)
- Jacquie Palmer (Pharmaceutical solutions)
- David Nowak (Henry Hughes IP)
- Chris Nave (Brandon Capital)
- Richard Stubbs and Bridget Stubbs (P3)
- Liz Smaill, Barney Montgomery and Penny Montgomery (Optimal Clinical Trials)